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Abstract  15
Key Findings: A large minority (coincidentally around 40%) of 
OST clients were using BZD at assessments, and at program reviews, 
and in urine drug screens and BZD were involved in a similar 
signifi cant proportion of unplanned treatment events. These are not 
however all the same clients. It appears that around 30% of clients 
either stop or start BZD use within treatment.
Interventions were developed regarding:
• provision of treatment for BZD dependence;
• risk management for BZD misuse; and
• environmental safety work and response to aggression.
Implications: BZD misuse is not inevitable in OTP clinics despite 
easy availability. Clear structures and clinical responses to BZD use 
can reduce some of the more negative aspects of clinic based drug 
treatment and enable clients to use treatment more effectively.
Conclusion: BZD use is widespread within OST but can be more 
effectively managed by developing staff skills and confi dence to 
reduce overt indications to a tolerable level.
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The last two decades has seen an expansion of prescribed opioids for 
patients with chronic pain. Practitioners face the dilemma of 
prescribing opioids to relieve pain for selected patients while avoiding 
misuse or diversion. Some practitioners lack the knowledge and 
training to fully assess patients with complex chronic pain syndromes 
or to rationally prescribe opioids. Others fail to recognise and 
adequately treat, or know when to refer, patients with mental health 
disorders that often accompany chronic pain. Psychological drivers 
of inappropriate opioid prescribing include relief of life stressors, 
diffi cult temperament and personality traits, unrecognised and 
untreated depression, somatising and/or hypochondrical features, 
malingering behaviour, psychosomatic disorders, moderate to severe 
anxiety, and intrusing negative cognitions. Other drivers include 
immediate-release opioids prescribed on an ‘as-required’ basis, 
problematic opioid withdrawal, loss of analgesic effi cacy, and 
unrecognised medical conditions. Practitioners are sometimes 
‘forced’ to continue inappropriate prescribing of opioids due to 
diffi culties obtaining consultative assistance. Opioid compliance is 
often the only method for judging patient trustworthiness, especially 
as self-reporting (testimony), and the reason for seeking opioids 
(motive), cannot be measured. Aggressive behaviours may coerce 
the practitioner to continue inappropriate prescribing of opioids. 
There exists a subset of individuals (criminals) who use the guise of 
a ‘chronic pain illness’ to obtain prescription opioids with the 
intention of selling for profi t. Practitioners who fail to recognise the 
warning features of addiction run the risk of prescribing opioids to 
addicts.
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Introduction and Aims: ’Cannabis Withdrawal Syndrome’ is 
proposed in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) due for release May 2013. Problematic cannabis 
use among remote Indigenous communities has been reported in 
Northern Territory and Queensland studies. When cannabis use is 
curtailed, many suffer symptoms which can lead to violence, threats, 
intimidation, sleep disturbances and heightened risk factors of self-
harm. Sudden cessation of cannabis use by detainees and inmates 
could further increase risk. Despite patterns of high cannabis use, 
dependence and demonstrated risk factors, whether Indigenous 
detainees/inmates experience withdrawal differently has not been 
considered.
Design and Methods: Dependent cannabis users who identify as 
Indigenous (Aboriginal and/or Torres Strait Island) aged between 
18–40 years will be recruited from far north Queensland police watch 
houses/Correctional Centres. Interviews with new detainees/inmates 
will occur on eight different occasions over 28 days. Assessments 
validated with biological markers, will examine onset and severity of 
cannabis withdrawal and psychological distress.
Results: Retrospective pilot data interviews will be presented along 
with preliminary fi ndings of the current study. Pilot data revealed 
70% (n = 70) of male inmates used cannabis before incarceration 
with 63% (n = 44) meeting dependence. The average number 
symptoms using DSM-5 criteria was 2.9 and included irritability/
anger/aggression, nervousness/anxiety, sleep diffi culties, depression 
and physical symptoms.
Discussion and Conclusions: To improve assessment and timely 
treatment of cannabis withdrawal within custodial settings, studies 
are needed to document onset and severity of symptoms and to 
devise culturally-acceptable resources and support to assist new 
inmates/detainees to manage withdrawal. Findings from this study 
will inform the DSM-5, for cultural variations and considerations to 
the proposed criteria.
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Issue: In January 2010 the ACT Government legislated that all 
pharmacists providing opioid dependence treatment (ODT) services 
undertake training to ensure the safety and effi cacy of their practice. 
This was a signifi cant change in practice with some risk of the 
increased legislative burden being poorly received by pharmacists. An 
ongoing quality assurance program is used to ensure that the training 
meets legislative and professional requirements.
Approach: Pharmacists and other health professionals who attend 
ODT training conducted by the ACT Health Alcohol and Drug 
Services Senior Pharmacist are invited to complete an anonymous 
survey several months after training. A 5 point Likert scale with free 
text option is used to assess the infl uence of the training on 
pharmacists practice since completing the training. They are also 
asked to provide examples of practice changes that they have made, 
and whether they support the legislated training requirement.
Key Findings: Since October 2011, 151 surveys have been sent to 
pharmacists who have completed ODT training, with 94 returned 
(response rate = 62%). Key results are:
• 89% agreed that their confi dence in providing ODT had 
increased
• 70% reported that providing ODT had become more 
professionally rewarding
• 84% felt that they were providing a better and safer ODT service
• 96% supported legislated training.
